Table of Contents
Chapter 1. Research Methodology and Scope
- Market Segmentation and Scope
- Regional Coverage
- Objectives
- Research Methodology
Chapter 2. Executive Summary
- Market Landscape
- Market Size & Forecast
- Competitive Landscape
Chapter 3. Argininosuccinic Aciduria Market: Treatment Type Segment Trends, Size, and Future Outlook
- Treatment Type Segment Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Treatment Type Definitions, Technology Landscape
- Treatment Type Segment Market Drivers
- Product Launches
- Technology Launches
- Treatment Type Segment Market Restraints
Chapter 4. Argininosuccinic Aciduria Market: Route of Administration Segment Trends, Size, and Future Outlook
- Route of Administration Segment Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Route of Administration Definitions, Technology Landscape
- Route of Administration Segment Market Drivers
- Product Launches
- Technology Launches
- Route of Administration Segment Market Restraints
Chapter 5. Argininosuccinic Aciduria Market: Age Group Segment Trends, Size, and Future Outlook
- Age Group Segment Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Age Group Definitions, Technology Landscape
- Age Group Segment Market Drivers
- Product Launches
- Technology Launches
- Age Group Segment Market Restraints
Chapter 6. Argininosuccinic Aciduria Market: Distribution Channel Segment Trends, Size, and Future Outlook
- Distribution Channel Segment Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Distribution Channel Definitions, Technology Landscape
- Distribution Channel Segment Market Drivers
- Product Launches
- Technology Launches
- Distribution Channel Segment Market Restraints
Chapter 7. Argininosuccinic Aciduria Market: End User Segment Trends, Size, and Future Outlook
- End User Segment Market Size (US$), CAGR (%), and Forecast (2021-2031)
- End User Definitions, Technology Landscape
- End User Segment Market Drivers
- Product Launches
- Technology Launches
- End User Segment Market Restraints
Chapter 8. Argininosuccinic Aciduria Market: Dosage Form Segment Trends, Size, and Future Outlook
- Dosage Form Segment Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Dosage Form Definitions, Technology Landscape
- Dosage Form Segment Market Drivers
- Product Launches
- Technology Launches
- Dosage Form Segment Market Restraints
Chapter 9. Argininosuccinic Aciduria Market: Regional Market Trends, Size, and Future Outlook
- North America
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Europe
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Asia Pacific
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Latin America
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Middle East, and Africa
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
Chapter 10. Argininosuccinic Aciduria Market: Competitive Landscape
- Horizon Therapeutics
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Ultragenyx Pharmaceutical
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Aeglea BioTherapeutics
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Homology Medicines
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Codiak BioSciences
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Audentes Therapeutics (acquired by Astellas Pharma)
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Modalis Therapeutics
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
Research Methodology
- Primary Research
- Secondary Research
- Assumptions
- IDataAcumen Analysis
- Paid Databases
Appendix
- About Us
Frequently Asked Questions
The current market size of the Argininosuccinic Aciduria industry is estimated to be USD 120 million.
Increasing prevalence of inherited metabolic disorders, rising awareness and early diagnosis, advancements in diagnostic techniques, growing demand for effective treatments, development of innovative therapies, expansion of newborn screening programs, and improving healthcare infrastructure in emerging markets.
High treatment costs, lack of approved therapies, challenges in disease management, limited availability of specialized care, low disease awareness in certain regions, and regulatory hurdles for orphan drug development.
The leading component segment in the Argininosuccinic Aciduria Market is the Dietary Management segment, which involves protein restriction and amino acid supplementation.
The major players operating in the Argininosuccinic Aciduria Market include Horizon Therapeutics, Ultragenyx Pharmaceutical, Aeglea BioTherapeutics, Homology Medicines, Codiak BioSciences, Audentes Therapeutics (acquired by Astellas Pharma), Modalis Therapeutics, and Lucane Biosciences.
The global Argininosuccinic Aciduria Market is expected to reach US$ 266.7 Million by 2031, with a growth rate of 10.5% during the forecast period.
Increasing prevalence of inherited metabolic disorders, rising awareness and early diagnosis, advancements in diagnostic techniques, growing demand for effective treatments, development of innovative therapies, expansion of newborn screening programs, and improving healthcare infrastructure in emerging markets.